Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTEND-CIU: Omalizumab in Chronic Idiopathic Urticaria
NCT02392624Phase 4Completed
- Sponsor
- Genentech
- Start
- May 2015
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Genentech. Started May 2015; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT02392624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392624.